Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA);Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes

Revista Argentina de Microbiologia

Volumn 39, Issue 3, 2007, Pages 138-142

  Ferrer, M F ^a,b   Zanetti, F A ^a,b,c   Calamante, G ^a  

^a INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c ANPCyT   (Argentina)

Author keywords

MVA; Non replicative viral vector; Poxvirus

Indexed keywords

BETA GALACTOSIDASE; BETA GLUCURONIDASE; VIRUS VECTOR;

ARTICLE; GENE EXPRESSION; GENE INSERTION; GENE LAC Z; GENE VECTOR; MODIFIED VACCINIA VIRUS ANKARA; MOLECULAR CLONING; NONHUMAN; UID A GENE; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINATION; VIRUS REPLICATION;

ANIMALS; CHICK EMBRYO; CLONING, MOLECULAR; DEFECTIVE VIRUSES; DNA, RECOMBINANT; GENES, REPORTER; GENES, VIRAL; GENETIC VECTORS; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 35448964774     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Antoine G, Scheiflinger F, Holzer G, Langmann T, Falkner FG, Dorner F. Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes. Gene 1996; 177: 43-6.
2. Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, Forsdyke J, et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006; 42: 1102-10.
3. Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2006; 24: 1180-90.
4. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997; 238: 198-211.
5. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79: 347-52.
6. Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 2005; 86: 2925-36.
7. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004; 172: 6209-20.
8. Horig H, Kaufman HL. Local delivery of poxvirus vaccines for melanoma. Semin Cancer Biol 2003; 13: 417-22.
9. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 1240-4. Erratum in: Nat Med 2004; 10: 1397.
10. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc Natl Acad Sci USA 1996; 93: 11341-48.
11. Paoletti E, Lipinskas B, Samsonoff C, Mercer S, Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 1984; 81: 193-7.
12. Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Com Immunol Micobiol and Infect Dis 2003; 26: 343-55.
13. Scheiflinger F, Falkner FG, Dorner F. Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain. Arch Virol 1996; 141: 663-9.
14. Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995; 13: 539-49.
15. Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 2004; 112: 461-70.